Jaylen Brown: Everything you need to know

Jaylen Brown

#7 SF

Boston Celtics

Status

ACTIVE

STATS

Career Averages

PTS

REB

AST

BLK

STL

20.0

5.5

2.9

0.4

1.0

Year	GP	GS	MIN	PTS	REB	AST	BLK	STL	TO	DD2	TD3	3PM	3PA	3P%	2PM	2PA	2P%	FGM	FGA	FG%	FTM	FTA	FT%	OREB	DREB	PF	A/TO	+/-	TS%
2025-26	71	71	34.4	28.7	6.9	5.1	0.4	1.0	3.6	14	3	2.0	5.7	34.7%	8.4	16.0	52.3%	10.4	21.7	47.7%	6.0	7.5	79.5%	1.1	5.8	2.7	1.4	+321	57.3%
2024-25	63	63	34.3	22.2	5.8	4.5	0.3	1.2	2.6	5	0	1.8	5.7	32.4%	6.4	12.1	52.9%	8.2	17.7	46.3%	3.9	5.1	76.4%	1.3	4.5	2.4	1.8	+402	55.5%
2023-24	70	70	33.5	23.0	5.5	3.6	0.5	1.2	2.4	6	1	2.1	5.9	35.4%	6.9	12.1	57.0%	9.0	17.9	49.9%	3.0	4.3	70.3%	1.2	4.3	2.6	1.5	+413	58.0%
2022-23	67	67	35.9	26.6	6.9	3.5	0.4	1.1	2.9	13	0	2.4	7.3	33.5%	7.7	13.4	57.6%	10.1	20.6	49.1%	3.9	5.1	76.5%	1.2	5.7	2.6	1.2	+256	58.1%
2021-22	66	66	33.6	23.6	6.1	3.5	0.3	1.1	2.7	11	2	2.5	7.0	35.8%	6.2	11.4	54.4%	8.7	18.4	47.3%	3.7	4.8	75.8%	0.8	5.3	2.5	1.3	+453	57.4%
2020-21	58	58	34.5	24.7	6.0	3.4	0.6	1.2	2.7	10	0	2.8	7.1	39.7%	6.5	12.1	53.6%	9.3	19.2	48.4%	3.3	4.3	76.4%	1.2	4.8	2.9	1.2	+69	58.6%
2019-20	57	57	33.9	20.3	6.4	2.1	0.4	1.1	2.2	8	0	2.3	5.9	38.2%	5.2	9.6	54.3%	7.5	15.6	48.1%	3.1	4.3	72.4%	1.1	5.3	2.9	0.9	+229	58.3%
2018-19	74	25	25.9	13.0	4.2	1.4	0.4	0.9	1.3	2	0	1.3	3.7	34.4%	3.7	7.0	52.9%	5.0	10.7	46.5%	1.8	2.7	65.8%	0.9	3.4	2.5	1.0	+66	54.7%
2017-18	70	70	30.7	14.5	4.9	1.6	0.4	1.0	1.8	2	0	1.7	4.4	39.5%	3.6	7.1	50.7%	5.3	11.5	46.5%	2.1	3.3	64.4%	0.9	4.0	2.6	0.9	+335	56.2%
2016-17	78	20	17.4	6.6	2.8	0.8	0.2	0.4	0.9	0	0	0.6	1.7	34.1%	1.9	3.7	50.7%	2.5	5.4	45.4%	1.1	1.6	68.5%	0.6	2.2	1.8	0.9	+0	53.9%
Career	674	567	31.0	20.0	5.5	2.9	0.4	1.0	2.3	71	6	1.9	5.3	35.8%	5.6	10.3	54.0%	7.5	15.6	47.8%	3.1	4.3	73.9%	1.0	4.5	2.5	1.3	+2544	57.1%

Career Averages

PTS

REB

AST

BLK

STL

19.3

5.7

2.6

0.4

1.0

Year	GP	GS	MIN	PTS	REB	AST	BLK	STL	TO	DD2	3PM	3PA	3P%	2PM	2PA	2P%	FGM	FGA	FG%	FTM	FTA	FT%	OREB	DREB	PF	A/TO	+/-	TS%
2024-25	11	11	36.5	22.1	7.1	3.9	0.3	1.0	3.5	3	1.9	5.7	33.3%	5.9	12.0	49.2%	7.8	17.7	44.1%	4.5	6.0	75.8%	1.2	5.9	3.2	1.1	+60	54.2%
2023-24	19	19	37.2	23.9	5.9	3.3	0.6	1.2	2.7	0	1.9	5.8	32.7%	7.3	12.1	60.7%	9.2	17.8	51.6%	3.6	5.4	66.0%	1.2	4.8	2.7	1.2	+88	59.1%
2022-23	20	20	37.6	22.7	5.6	3.4	0.4	1.1	3.3	2	2.0	5.7	35.4%	7.1	12.6	56.0%	9.1	18.3	49.6%	2.6	3.7	68.9%	1.3	4.4	3.1	1.0	+42	57.0%
2021-22	24	24	38.3	23.1	6.9	3.5	0.4	1.1	3.1	2	2.5	6.7	37.3%	5.7	10.8	53.1%	8.2	17.5	47.0%	4.2	5.5	76.3%	1.4	5.5	3.0	1.1	+73	58.1%
2019-20	17	17	39.5	21.8	7.5	2.3	0.5	1.5	2.4	2	2.5	7.1	35.8%	5.5	9.9	56.0%	8.1	16.9	47.6%	3.1	3.7	84.1%	1.4	6.1	2.8	1.0	+47	58.6%
2018-19	9	9	30.4	13.9	5.8	1.1	0.2	0.7	1.8	0	1.6	4.4	35.0%	3.3	5.2	63.8%	4.9	9.7	50.6%	2.6	3.3	76.7%	0.7	5.1	3.3	0.6	-44	62.4%
2017-18	18	15	32.4	18.0	4.8	1.4	0.6	0.8	1.3	0	2.4	6.2	39.3%	4.4	8.6	51.9%	6.9	14.8	46.6%	1.8	2.8	64.0%	0.9	3.9	3.2	1.1	+22	56.3%
2016-17	17	0	12.6	5.0	2.1	0.8	0.1	0.4	0.8	0	0.3	1.4	21.7%	1.7	2.8	60.4%	2.0	4.2	47.9%	0.7	1.1	66.7%	0.7	1.4	1.5	1.0	+0	53.9%
Career	135	115	33.5	19.3	5.7	2.6	0.4	1.0	2.4	9	1.9	5.5	35.4%	5.3	9.5	55.5%	7.2	15.0	48.2%	2.9	4.0	72.7%	1.1	4.6	2.8	1.1	+288	57.6%

Preseason
Date	Opp	Result	MIN	PTS	REB	AST	BLK	STL	TO	3PA	3PM	3P%	2PA	2PM	2P%	FGA	FGM	FG%	FTA	FTM	FT%	OREB	DREB	A/TO	+/-	PF	PER	TS%
10/15	TOR	W 110-108	7	7	2	0	0	1	0	3	1	33.3%	1	1	100.0%	4	2	50.0%	2	2	100.0%	1	1	0.0	+9	0	9	71.7%
10/12	CLE	W 138-107	21	8	5	6	1	3	4	1	0	0.0%	5	2	40.0%	6	2	33.3%	6	4	66.7%	1	4	1.5	+23	1	16	46.3%
10/8	MEM	W 121-103	20	21	1	0	0	0	2	6	3	50.0%	7	3	42.9%	13	6	46.2%	8	6	75.0%	0	1	0.0	+15	2	12	63.6%
Preseason Totals			16.4	12.0	2.7	2.0	0.3	1.3	2.0	3.3	1.3	40.0%	4.3	2.0	46.2%	7.7	3.3	43.5%	5.3	4.0	75.0%	0.7	2.0	1.0	+47	1.0	14.0	59.9%

Regular Season
Date	Opp	Result	MIN	PTS	REB	AST	BLK	STL	TO	3PA	3PM	3P%	2PA	2PM	2P%	FGA	FGM	FG%	FTA	FTM	FT%	OREB	DREB	A/TO	+/-	PF	PER	TS%
4/7	CHA	W 113-102	43	35	9	3	1	1	5	10	3	30.0%	19	10	52.6%	29	13	44.8%	7	6	85.7%	0	9	0.6	+9	2	30	54.6%
4/5	TOR	W 115-101	35	26	6	3	0	2	5	3	1	33.3%	17	10	58.8%	20	11	55.0%	5	3	60.0%	3	3	0.6	+13	2	21	58.6%
4/3	MIL	W 133-101	30	26	3	4	0	2	2	4	2	50.0%	13	5	38.5%	17	7	41.2%	11	10	90.9%	0	3	2.0	+27	3	23	59.5%
4/1	MIA	W 147-129	37	43	3	7	0	0	1	10	4	40.0%	19	13	68.4%	29	17	58.6%	7	5	71.4%	1	2	7.0	+9	3	40	67.0%
3/30	ATL	L 112-102	40	29	10	9	0	1	6	9	3	33.3%	20	6	30.0%	29	9	31.0%	14	8	57.1%	1	9	1.5	-5	3	19	41.2%
3/25	OKC	W 119-109	38	31	8	8	0	2	5	3	1	33.3%	14	8	57.1%	17	9	52.9%	14	12	85.7%	2	6	1.6	+7	4	40	66.9%
3/22	MIN	L 102-92	35	29	7	4	0	0	3	6	2	33.3%	20	7	35.0%	26	9	34.6%	11	9	81.8%	0	7	1.3	-8	1	23	47.0%
3/20	MEM	W 117-112	38	30	6	6	0	0	1	5	2	40.0%	18	8	44.4%	23	10	43.5%	8	8	100.0%	2	4	6.0	+9	3	28	56.6%
3/18	GSW	W 120-99	35	32	6	5	0	2	5	4	1	25.0%	16	10	62.5%	20	11	55.0%	9	9	100.0%	2	4	1.0	+23	3	36	66.8%
3/16	PHX	W 120-112	39	41	7	6	1	1	4	5	2	40.0%	15	8	53.3%	20	10	50.0%	21	19	90.5%	1	6	1.5	+9	0	50	70.1%
3/14	WAS	W 111-100	30	16	4	3	0	1	3	5	0	0.0%	8	6	75.0%	13	6	46.2%	4	4	100.0%	2	2	1.0	+8	1	14	54.2%
3/12	OKC	L 104-102	40	34	6	7	1	2	6	4	1	25.0%	21	9	42.9%	25	10	40.0%	14	13	92.9%	1	5	1.2	-10	5	29	54.6%
3/10	SAS	L 125-116	14	8	2	7	0	1	2	0	0	0.0%	8	4	50.0%	8	4	50.0%	0	0	0.0%	0	2	3.5	+1	2	9	50.0%
3/8	CLE	W 109-98	37	23	9	8	0	0	4	3	1	33.3%	14	6	42.9%	17	7	41.2%	9	8	88.9%	3	6	2.0	+17	5	27	54.9%
3/6	DAL	W 120-100	33	24	7	7	0	2	3	5	2	40.0%	12	7	58.3%	17	9	52.9%	6	4	66.7%	3	4	2.3	+20	1	31	61.1%
3/4	CHA	L 118-89	33	20	11	7	0	0	3	4	1	25.0%	15	6	40.0%	19	7	36.8%	6	5	83.3%	1	10	2.3	-20	1	24	46.2%
3/1	PHI	W 114-98	38	27	8	8	0	0	5	6	2	33.3%	11	7	63.6%	17	9	52.9%	7	7	100.0%	2	6	1.6	+7	1	34	67.2%
2/27	BKN	W 148-111	29	28	7	9	1	2	2	4	4	100.0%	8	5	62.5%	12	9	75.0%	10	6	60.0%	0	7	4.5	+25	3	40	85.4%
2/25	DEN	L 103-84	33	23	11	3	3	0	4	6	1	16.7%	15	6	40.0%	21	7	33.3%	9	8	88.9%	0	11	0.8	-12	2	23	46.1%
2/22	LAL	W 111-89	36	32	8	7	0	3	5	9	3	33.3%	19	7	36.8%	28	10	35.7%	12	9	75.0%	0	8	1.4	+18	3	25	48.1%
2/19	GSW	W 121-110	37	23	15	13	0	0	2	3	0	0.0%	15	10	66.7%	18	10	55.6%	3	3	100.0%	0	15	6.5	+11	3	42	59.5%
2/11	CHI	W 124-105	28	24	4	4	0	0	2	9	2	22.2%	11	7	63.6%	20	9	45.0%	4	4	100.0%	0	4	2.0	+15	1	18	55.1%
2/8	NYK	L 111-89	33	26	2	4	1	1	2	4	0	0.0%	21	11	52.4%	25	11	44.0%	4	4	100.0%	0	2	2.0	-14	3	19	48.6%
2/6	MIA	W 98-96	33	29	7	2	1	0	7	7	1	14.3%	18	10	55.6%	25	11	44.0%	10	6	60.0%	1	6	0.3	-16	2	16	49.3%
2/3	DAL	W 110-100	37	33	11	3	0	1	3	5	2	40.0%	24	13	54.2%	29	15	51.7%	2	1	50.0%	1	10	1.0	-1	4	28	55.2%
2/1	MIL	W 107-79	29	30	13	2	0	1	4	6	4	66.7%	14	8	57.1%	20	12	60.0%	3	2	66.7%	1	12	0.5	+16	1	37	70.4%
1/28	ATL	L 117-106	29	21	7	3	1	0	3	5	0	0.0%	15	9	60.0%	20	9	45.0%	4	3	75.0%	0	7	1.0	-24	2	19	48.3%
1/26	POR	W 102-94	36	20	8	4	0	4	1	3	1	33.3%	14	7	50.0%	17	8	47.1%	5	3	60.0%	1	7	4.0	+6	1	24	52.1%
1/24	CHI	L 114-111	37	33	8	5	1	1	2	8	2	25.0%	20	12	60.0%	28	14	50.0%	4	3	75.0%	0	8	2.5	-13	1	35	55.4%
1/23	BKN	W 130-126	45	27	10	12	0	1	2	10	4	40.0%	17	5	29.4%	27	9	33.3%	10	5	50.0%	1	9	6.0	+11	2	30	43.0%
1/21	IND	W 119-104	33	30	10	5	0	3	5	2	1	50.0%	20	10	50.0%	22	11	50.0%	9	7	77.8%	2	8	1.0	+11	2	34	57.8%
1/19	DET	L 104-103	38	32	11	2	1	0	4	8	2	25.0%	20	9	45.0%	28	11	39.3%	10	8	80.0%	4	7	0.5	+2	3	27	49.4%
1/17	ATL	W 132-106	29	41	6	2	1	1	1	9	2	22.2%	21	12	57.1%	30	14	46.7%	12	11	91.7%	1	5	2.0	+36	0	37	58.1%
1/15	MIA	W 119-114	30	27	7	0	0	0	5	7	2	28.6%	17	7	41.2%	24	9	37.5%	7	7	100.0%	2	5	0.0	-10	3	17	49.9%
1/10	SAS	L 100-95	43	27	8	7	0	0	5	11	5	45.5%	17	6	35.3%	28	11	39.3%	0	0	0.0%	0	8	1.4	-1	4	19	48.2%
1/9	TOR	W 125-117	36	25	8	7	0	0	4	3	1	33.3%	12	5	41.7%	15	6	40.0%	13	12	92.3%	1	7	1.8	+17	0	33	60.3%
1/7	DEN	L 114-110	34	33	7	4	0	1	7	6	4	66.7%	23	10	43.5%	29	14	48.3%	3	1	33.3%	1	6	0.6	-14	5	17	54.4%
1/5	CHI	W 115-101	34	14	8	4	0	0	3	6	1	16.7%	18	5	27.8%	24	6	25.0%	2	1	50.0%	3	5	1.3	+12	2	3	28.1%
1/3	LAC	W 146-115	35	50	3	5	0	0	2	10	6	60.0%	16	12	75.0%	26	18	69.2%	10	8	80.0%	1	2	2.5	+21	3	49	82.2%
1/1	SAC	W 120-106	34	29	10	4	0	0	5	9	1	11.1%	16	10	62.5%	25	11	44.0%	7	6	85.7%	1	9	0.8	-2	6	22	51.6%
12/30	UTA	W 129-119	33	23	6	10	0	2	2	3	1	33.3%	16	8	50.0%	19	9	47.4%	6	4	66.7%	1	5	5.0	+2	1	28	53.1%
12/28	POR	L 114-108	36	37	7	4	0	0	6	5	2	40.0%	18	12	66.7%	23	14	60.9%	10	7	70.0%	1	6	0.7	+0	5	30	67.5%
12/26	IND	W 140-122	32	30	3	4	0	4	4	3	2	66.7%	17	11	64.7%	20	13	65.0%	2	2	100.0%	1	2	1.0	+19	4	29	71.8%
12/22	IND	W 103-95	33	31	9	2	2	1	2	6	2	33.3%	19	9	47.4%	25	11	44.0%	8	7	87.5%	1	8	1.0	-2	1	32	54.3%
12/19	MIA	W 129-116	34	30	9	7	0	1	5	4	2	50.0%	14	7	50.0%	18	9	50.0%	11	10	90.9%	0	9	1.4	+8	3	36	65.7%
12/15	DET	L 112-105	40	34	8	7	3	1	4	5	1	20.0%	20	12	60.0%	25	13	52.0%	14	7	50.0%	4	4	1.8	-6	2	32	54.6%
12/11	MIL	L 116-101	28	30	3	3	0	0	4	4	2	50.0%	13	8	61.5%	17	10	58.8%	9	8	88.9%	1	2	0.8	-15	3	28	71.6%
12/7	TOR	W 121-113	38	30	8	5	1	1	3	4	3	75.0%	15	6	40.0%	19	9	47.4%	9	9	100.0%	4	4	1.7	+18	1	40	65.3%
12/5	LAL	W 126-105	33	30	8	8	0	1	3	7	3	42.9%	15	7	46.7%	22	10	45.5%	9	7	77.8%	1	7	2.7	+12	3	37	57.8%
12/2	NYK	W 123-117	39	42	4	4	0	1	4	6	2	33.3%	18	14	77.8%	24	16	66.7%	9	8	88.9%	0	4	1.0	+15	3	41	75.1%
11/30	CLE	W 117-115	37	19	12	11	0	1	6	4	1	25.0%	9	2	22.2%	13	3	23.1%	16	12	75.0%	1	11	1.8	+16	3	32	47.4%
11/29	MIN	L 119-115	39	41	6	7	1	5	4	11	5	45.5%	21	12	57.1%	32	17	53.1%	4	2	50.0%	2	4	1.8	+1	3	41	60.7%
11/26	DET	W 117-114	34	33	10	5	2	2	5	7	2	28.6%	25	10	40.0%	32	12	37.5%	8	7	87.5%	3	7	1.0	-9	4	23	46.5%
11/23	ORL	W 138-129	37	35	4	8	0	1	1	6	2	33.3%	20	12	60.0%	26	14	53.8%	7	5	71.4%	1	3	8.0	+12	3	32	60.2%
11/21	BKN	L 113-105	31	26	8	4	0	2	3	4	1	25.0%	14	8	57.1%	18	9	50.0%	9	7	77.8%	1	7	1.3	-4	5	27	59.2%
11/18	BKN	W 113-99	32	29	4	4	0	1	8	7	3	42.9%	12	6	50.0%	19	9	47.4%	10	8	80.0%	1	3	0.5	+2	2	23	62.0%
11/16	LAC	W 121-118	38	33	13	3	1	2	1	7	1	14.3%	26	13	50.0%	33	14	42.4%	7	4	57.1%	3	10	3.0	+22	1	32	45.7%
11/12	MEM	W 131-95	25	19	6	6	0	0	2	5	2	40.0%	11	6	54.5%	16	8	50.0%	2	1	50.0%	3	3	3.0	+29	2	19	56.3%
11/11	PHI	L 102-100	35	24	6	5	0	0	2	3	1	33.3%	15	7	46.7%	18	8	44.4%	8	7	87.5%	1	5	2.5	-5	2	29	55.8%
11/9	ORL	W 111-107	33	27	5	1	1	1	4	4	1	25.0%	20	9	45.0%	24	10	41.7%	7	6	85.7%	1	4	0.3	-17	4	15	49.9%
11/7	ORL	L 123-110	36	32	9	3	0	1	4	6	1	16.7%	22	14	63.6%	28	15	53.6%	2	1	50.0%	0	9	0.8	-21	3	25	55.4%
11/5	WAS	W 136-107	25	35	5	5	0	1	1	4	2	50.0%	17	11	64.7%	21	13	61.9%	9	7	77.8%	1	4	5.0	+11	2	37	70.1%
11/3	UTA	L 105-103	37	36	2	4	0	2	3	9	0	0.0%	19	13	68.4%	28	13	46.4%	11	10	90.9%	1	1	1.3	+21	3	31	54.8%
11/1	HOU	L 128-101	21	12	2	5	0	1	5	2	0	0.0%	12	6	50.0%	14	6	42.9%	0	0	0.0%	0	2	1.0	-20	3	5	42.9%
10/31	PHI	W 109-108	31	32	3	6	1	1	5	7	4	57.1%	12	9	75.0%	19	13	68.4%	3	2	66.7%	1	2	1.2	-11	4	31	78.7%
10/29	CLE	W 125-105	31	30	5	4	1	1	2	9	4	44.4%	11	8	72.7%	20	12	60.0%	2	2	100.0%	0	5	2.0	+20	4	32	71.8%
10/27	NOP	W 122-90	24	15	7	4	0	0	3	3	1	33.3%	6	4	66.7%	9	5	55.6%	6	4	66.7%	0	7	1.3	+4	5	18	64.4%
10/26	DET	L 119-113	35	41	6	4	0	0	4	9	5	55.6%	16	7	43.8%	25	12	48.0%	15	12	80.0%	2	4	1.0	-1	3	39	64.9%
10/24	NYK	L 105-95	35	23	4	3	1	1	7	7	3	42.9%	11	6	54.5%	18	9	50.0%	4	2	50.0%	0	4	0.4	-14	5	14	58.2%
10/22	PHI	L 117-116	36	25	6	4	0	0	2	4	2	50.0%	14	7	50.0%	18	9	50.0%	6	5	83.3%	0	6	2.0	+0	4	24	60.6%
Regular Season Totals			34.5	28.8	7.0	5.2	0.4	1.0	3.6	5.7	2.0	34.4%	16.1	8.4	52.3%	21.9	10.4	47.6%	7.6	6.0	79.6%	1.2	5.8	1.4	+297	2.7	32.1	57.2%

Jaylen Brown: Breaking News

Brown (Achilles) isn't listed on the injury report for Sunday's Game 1 against the 76ers. Brown sat out Boston's regular-season finale due to Achilles tendinitis but is good to go for the start of the playoffs. In five regular-season appearances during April, the star swingman averaged 30.6 points, 4.8 rebounds, 3.6 assists and 1.2 steals in 34.8 minutes per game.

Brown (Achilles) has been ruled out for Sunday's regular-season finale against the Magic, Taylor Snow of the Celtics' official site reports. The Celtics have locked up the No. 2 seed in the East, so there's not much incentive for Brown to play through Achilles tendinitis in Boston's final game of the regular season. Jayson Tatum (Achilles), Derrick White (knee) and Payton Pritchard (foot) are expected to join Brown on the sidelines Sunday, so guys like Baylor Scheierman, Hugo Gonzalez and Dalano Banton should be slated for major minutes and prominent roles on offense.

Brown (Achilles) is available for Friday's game versus New Orleans, Jay King of The Athletic reports. After sitting out Thursday's loss to the Knicks, the star forward is ready to return Friday. Brown has dropped at least 26 points in 10 consecutive games, and he should do the heavy lifting offensively Friday with Jayson Tatum (Achilles) out of action.